Citations

Clear

11 citation(s) found for "Blumenfeld, Sophia".

Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study
Hassoun, Mohamad Rani , Wang, Kenny Y. , Kim, B. Michelle, Blumenfeld, Sophia, Lum, Flora, Starr, Matthew R. , Lum, Flora

Mayo Clinic

Retina | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/iae.0000000000005015 | PMID 42765869 Get It

Purpose: The purpose of this study is to characterize the clinical features, management strategies, and outcomes of endophthalmitis cases following pars plana vitrectomy using data from the American Academy of Ophthalmology (Academy) IRIS ® Registry (Intelligent Research in Sight). Methods: This is a retrospective cohort study of eyes that developed endophthalmitis following pars plana vitrectomy between 2013 and 2022. Data was collected from the Academy IRIS Registry. This study analyzed differences in visual acuity, intraocular pressure, rates of evisceration and enucleation, and rates of rhegmatogenous retinal detachment following endophthalmitis diagnosis. Results: A total of 1,223,777 unique eyes underwent a PPV during the study period, with 1,275 eyes meeting the inclusion criteria. The median time from pars plana vitrectomy to endophthalmitis diagnosis was 10 days. The majority of eyes (80.9%) were managed with intravitreal antibiotics alone, without a repeat pars plana vitrectomy. Long-term visual acuity, intraocular pressure, cup-to-disc ratio, and rate of evisceration or enucleation did not differ significantly between treatment groups. However, eyes that underwent the initial pars plana vitrectomy for retinal detachment repair had poorer long-term vision and higher rates of retinal detachment following endophthalmitis. Overall, 16.1% of eyes required evisceration or enucleation in this cohort. Conclusions: Despite its rarity, post-pars plana vitrectomy endophthalmitis can cause significant morbidity and even globe loss. There were no significant differences observed between eyes that were treated with intravitreal tap and inject versus repeat pars plana vitrectomy.
Practice Variation in Antibiotic Duration for Acute Otitis Media in Children Aged 2 to 5 Years
Rivera-Sepúlveda, Andrea , Mohammad, Nabeel , Okocha, Adaobi, Li, Zhuo, Blumenfeld, Sophia, Zomorrodi, Arezoo , Li, Zhuo

Mayo Clinic

Pediatric Emergency Care | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pec.0000000000003670 | PMID 42552999 Get It

Background: Acute otitis media (AOM) is among the most common pediatric infections and a leading indication for antibiotic prescribing. Although current guidelines recommend 5 to 7 days of therapy for children 2 to 5 years of age with uncomplicated AOM, variation in antibiotic duration remains common. We evaluated whether a 5-day antibiotic course was associated with similar short-term outcomes compared with a 7-day course. Methods: We conducted a retrospective multicenter cohort study using electronic health record data from 44 pediatric emergency departments, urgent care centers, and primary care practices within an integrated health care system. Children 2 to 5 years of age with uncomplicated AOM treated with a single oral antibiotic during 2022 were included. The primary analysis compared children prescribed 5 versus 7 days of therapy. Treatment failure was defined as an AOM-related return encounter requiring a new systemic antibiotic prescription within 7 days after completion of therapy (EOT+7). Secondary analyses evaluated outcomes by antibiotic class and prespecified sensitivity analyses. Results: The final analytic cohort included 7528 children; 906 received 5-day therapy, and 1799 received 7-day therapy. Treatment failure occurred in 0.44% and 0.61%, respectively (absolute risk difference: −0.17%; 95% CI: −0.73 to 0.39; risk ratio: 0.72; 95% CI: 0.23-2.26). Findings were consistent across antibiotic-specific and sensitivity analyses. Conclusions: Among children 2 to 5 years of age with uncomplicated AOM, a 5-day antibiotic course was not associated with an increased risk of short-term treatment failure compared with a 7-day course, supporting guideline-concordant prescribing and outpatient antimicrobial stewardship.
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, Vrutti , Sujanyal, Saurabh Ashok , Raavi, Lekhya , Blumenfeld, Sophia G. , Saleem, Faiz , Bateh, Said , Hanson, Abby , Jena, Anek , Isha, Shahin , Pietrzak, Katheleen A. Rottman, Ojard, Michelle, Shah, Sadia Z. , Sanghavi, Devang , Anna, Shapiro, Sujanyal, Saurabh , Rottman Pietrzak, Katheleen A, Ojard, Michelle M , Huespe, Ivan Alfredo , Moreno Franco, Pablo , Edwards, Michael A. , Chauhan, Mohit , Sanghavi, Devang K , Shahin, Isha , Kunze, Katie L. , Johnson, Patrick W. , Pietrzak, Katheleen A., Huespe, Iván , Franco, Pablo Moreno , Chauhan, Mohit

Mayo Clinic

Journal of Intensive Care Medicine | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261438474 | PMID 41989186 Get It

Background Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.
Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Iqbal, M., Li, Zhuo, Blumenfeld, Sophia G. , Foran, J., Roy, Vivek, Ayala, Ernesto, Kharfan-Dabaja, M., Fan, Yao‐Shan, Jiang, Liuyan , Li, Zhuo , Blumenfeld, Sophia, Mahadevia, Himil , Murthy, Hemant S. , Foran, James M. , Roy, Vivek , Badar, Talha , Kharfan‐Dabaja, Mohamed A.

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | March 18, 2026 | Volume: 18 | Issue: 4 | Pages: 155-163

10.4103/hemoncstem.hemoncstem-d-25-00029 | PMID 41846455 Get It

Measurable residual disease (MRD) has established prognostic significance in patients with myeloid disorders; however, there is limited data regarding its prognostic and predictive value and the optimal technique for measurement in the setting of post allogeneic hematopoietic cell transplantation (allo-HCT). A multi-gene next generation sequencing (NGS) panel can overcome the limitations of conventional techniques for measurement of MRD and can shed light onto the longitudinal evolution and genomic complexity of patients undergoing allo-HCT for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study, patients with AML or MDS who underwent their first allo-HCT and completed NGS testing at day +100 and were in a state of morphological remission were identified from the transplant registry of Mayo Clinic in Florida. The primary aim was to evaluate the prognostic impact of somatic variants detected via NGS at day +100 post allo-HCT on long-term outcomes. In total, 105 patients who underwent allo-HCT for AML and MDS and completed NGS testing on day +100 were included in the study population. Seventeen patients were found to have detectable variants, and 88 patients were without a detectable variant. At a median follow up of 1.4 years (0.1–5.5), presence of any variant at day +100 was associated with inferior 4-year overall survival (OS) (32% vs. 69%, P < 0.001), decreased progression free survival (PFS) (34% vs. 61%, P < 0.001), and a higher incidence of relapse (64% vs. 23%, P < 0.001). In univariate models, a lower Karnofsky performance score and presence of variants post allo-HCT remained significantly associated with inferior OS, higher relapse incidence, and a decreased PFS. The presence of variants at day +100 post allo-HCT remained significant in multivariate models for relapse ( P = 0.002) but not for OS ( P = 0.06) and PFS ( P = 0.08). These results indicate that the presence of detectable somatic variants at day +100 is associated with poor long-term outcomes and are predictive of a higher incidence of relapse.
Association Between High-Flow Nasal Cannula Use for Bronchiolitis and Subsequent Asthma Diagnosis
Rivera-Sepúlveda, Andrea , Ammann, Lindsey M. , Hough, Arielle , Blumenfeld, Sophia G. , Li, Zhuo, Davis, Matthew M., Blake, Kathryn

Mayo Clinic

Pediatrics Open Science | January 12, 2026 | Volume: 2 | Issue: 1 | Pages: 1-8

10.1542/pedsos.2025-000603 Get It

BACKGROUND High-flow nasal cannula (HFNC) therapy is widely used in infants hospitalized with moderate-to-severe bronchiolitis. Although bronchiolitis severity has been consistently associated with later asthma, it remains unclear whether HFNC contributes additional risk or instead represents a marker of severe illness. We examined the relationship between HFNC use during bronchiolitis hospitalization and the subsequent hazard of asthma diagnosis in early childhood. METHODS We conducted a retrospective cohort study of 4736 children aged younger than 2 years hospitalized with bronchiolitis from 2015 to 2023 across 2 tertiary children’s hospitals. Children were stratified by HFNC exposure. Cox proportional hazards models evaluated the association between HFNC use and subsequent asthma diagnosis. Secondary analyses assessed HFNC duration and frequency. RESULTS Forty-three percent of children received HFNC. Asthma was subsequently diagnosed in 37% of HFNC-treated children and 22% of non-HFNC children (P &lt; .001). After adjustment for demographic and clinical variables, HFNC use was associated with a 40% increased hazard of subsequent asthma diagnosis (hazard ratio, 1.40; 95% CI, 1.24–1.57; P &lt; .001). No dose-response pattern was observed by HFNC duration or frequency. CONCLUSION HFNC use was associated with an increased hazard of subsequent diagnosis of asthma in childhood, likely reflecting underlying disease severity rather than a treatment-related effect. Prospective studies are needed to differentiate severity-related risk from treatment-associated factors to optimize respiratory support strategies for infants with bronchiolitis.
Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease
Gavrielatos, Marios , Heckman, Michael G. , Blumenfeld, Sophia G. , Hou, Xu , Koga, Shunsuke , Murray, Melissa E., Kasanuki, Koji , Ono, Daisuke , Fiesel, Fabienne C. , Uitti, Ryan J. , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Ertekin‐Taner, Nilüfer , Dalgard, Clifton L., Savica, Rodolfo , Graff‐Radford, Jonathan , Petersen, Ronald C. , Reichard, R. Ross , Graff‐Radford, Neill R., Ferman, Tanis J. , Boeve, Bradley F., Wszolek, Zbigniew K., Mignot, Emmanuel, Scholz, Sonja W. , Ross, Owen A. , Koga, Shunsuke , Fiesel, Fabienne C , Ramanan, Vijay K , Kantarci, Kejal , Savica, Rodolfo , Graff-Radford, Jonathan , Petersen, Ronald C , Gan-Or, Ziv , Scholz, Sonja W , Dickson, Dennis W , Ross, Owen A , Jack, Clifford R , Heckman, Michael G , Ferman, Tanis J , Soto‐Beasley, Alexandra I. , Hou, Xu , Murray, Melissa E. , Botha, Hugo , Ramanan, Vijay K. , Gibbs, J. Raphael , Traynor, Bryan J. , Graff‐Radford, Neill R. , Boeve, Bradley F. , Springer, Wolfdieter , Gan‐Or, Ziv , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | November 7, 2025 | Volume: 99 | Issue: 2 | Pages: 492-501

10.1002/ana.78075 | PMID 41200866 Get It

Objective Lewy body disease (LBD) is a complex neurodegenerative disorder characterized by the accumulation of misfolded α‐synuclein in the brain. Neuroinflammation has long been implicated in LBD pathogenesis, and recent genetic studies in Parkinson's disease (a clinical manifestation of LBD) have shown consistent association with the human leukocyte antigen (HLA) gene complex. Here, we assessed whether variation in HLA alleles influences neuropathological burden in a neuropathologically‐defined series of LBD cases. Methods We conducted a comprehensive analysis of HLA allelic variants in a cohort of 539 LBD cases of European descent from the Mayo Clinic brain bank. High‐resolution whole‐genome sequencing was used, and the HLA alleles of each sample were called using the HLA*LA tool and assessed for association with neuropathological outcomes. Results Our analysis identified 1 significant ( P < 3.43 × 10 −5 ) and 4 suggestive ( P < 0.001) associations between certain HLA alleles and specific neuropathological outcomes in LBD, suggesting a potential role for HLA‐mediated immune mechanisms in disease progression and subtype differentiation. Specifically, HLA‐DPB1*06:01 was significantly associated with lower Lewy body counts in the parahippocampal gyrus ( P = 3.30 × 10 −5 ), with weaker and suggestive associations observed in the middle frontal ( P = 1.80 × 10 −4 ) and inferior parietal gyrus ( P = 6.33 × 10 −4 ). Additionally, although only suggestive, HLA‐DRB1*11:01 correlated with a lower Thal amyloid phase ( P = 1.56 x 10 −4 ), and HLA‐B*15:01 correlated with an increased risk of diffuse LBD ( P = 7.58 x 10 −4 ). Interpretation This study provides a detailed evaluation of the relationship between HLA alleles and LBD pathology, highlighting the importance of immune‐related genetic factors in the etiology of LBD. ANN NEUROL 2026;99:492–501
Perspectives of US Medical Residency and Fellowship Applicants on No-Stakes Campus Visits
Garner, Hillary W. , Christiansen, John D., Blumenfeld, Sophia G. , Christiansen, Ashley M., Makhtin, Maya, Mauricio, Elizabeth A. , Carey, William A., Sadosty, Annie T., Tolaymat, Leila , Garner, Hillary W , Heckman, Michael G. , Mauricio, Elizabeth A. , West, Colin P.

Mayo Clinic

Journal of Graduate Medical Education | August 14, 2024 | Volume: 16 | Issue: 4 | Pages: 475-478

10.4300/jgme-d-23-00842.1 | PMID 39148885 Get It

ABSTRACT Background Virtual interviews may limit an applicant’s ability to ascertain the culture of a training program. No-stakes campus visits (NSCVs) have been offered but their value is unknown. Objective The purpose of our study was to determine factors that influence applicants’ rank lists and determine barriers to and perceptions of NSCVs and their impact on applicants’ final rank lists. Methods All interviewed applicants of graduate medical education (GME) programs who agreed to participate in the study were emailed a survey after the 2023 National Resident Matching Program Match. The survey contained sections on demographics, perspectives on factors affecting ranking decisions, and perceptions of NSCVs. Results Of 796 applicants, 183 (22.9%) who interviewed at 16 different Mayo Clinic GME programs responded to the survey. Of 131 respondents who answered whether they accepted an NSCV offer, 39 (29.8%) accepted. Of 35 respondents who answered whether they thought attending NSCVs impacted their rank, 19 (54.3%) were either uncertain or said yes. Of 34 respondents who answered whether the NSCV influenced their ranking of the program, 16 (47.1%) said their rank did not change, 12 (35.3%) said they ranked the program higher, and 5 (14.7%) said they ranked the program lower. For respondents who did not attend NSCVs, financial burden and lack of time were primary reasons. Conclusions NSCVs are perceived positively by most respondents. Many either believed they influenced their position on the program’s rank list or were unsure. Most respondents said NSCVs either improved or did not change their ranking of the program.